Slc12a5^tm2.1Geno
Targeted Allele Detail

Summary

• Symbol: Slc12a5^tm2.1Geno
• Name: solute carrier family 12, member 5; targeted mutation 2.1, Genoway
• MGI ID: MGI:6755215
• Synonyms: KCC2-T906A/T1007A
• Gene: Slc12a5 Location: Chr2:164802766-164841651 bp, + strand Genetic Position: Chr2, 85.28 cM, cytoband G2-G3
• Alliance: Slc12a5^tm2.1Geno page

Mutation origin

• Germline Transmission: Earliest citation of germline transmission: J:265906
• Parent Cell Line: Not Specified (ES Cell)
• Strain of Origin: Not Specified

Mutation description

• Allele Type: Targeted (Not Applicable)
• Mutation: Nucleotide substitutions
• Mutation details: An ACA to GCC change resulting in a threonine to alanine substitution at amino acid 906 (T906A) and an ACC to GCC change resulting in a threonine to alanine substitution at amino acid 1007 (T1007A) were inserted into exons 22 and exon 24, respectively. A loxP-flanked neomycin selection cassette inserted between exon 22 and 23 was removed via cre-mediated recombination. (J:265906)

Find Mice (IMSR)

• Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)
• Carrying this Mutation: Mouse Strains: 0 strains available Cell Lines: 0 lines available
• Carrying any Slc12a5 Mutation: 46 strains or lines available

References

• Original: J:265906 Moore YE, et al., Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures. Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10166-10171
• All: 3 reference(s)